Accessibility Menu
 
Emergent BioSolutions logo

Emergent BioSolutions

(NYSE) EBS

Current Price$8.05
Market Cap$414.71M
Since IPO (2006)-27%
5 Year-87%
1 Year+50%
1 Month-2%

Emergent BioSolutions Financials at a Glance

Market Cap

$414.71M

Revenue (TTM)

$742.90M

Net Income (TTM)

$52.60M

EPS (TTM)

$0.83

P/E Ratio

9.68

Dividend

$0.00

Beta (Volatility)

1.78 (High)

Price

$8.05

Volume

190,789.578

Open

$8.00

Previous Close

$8.03

Daily Range

$8.00 - $8.21

52-Week Range

$4.71 - $14.06

EBS: Motley Fool Moneyball Superscore

57

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Emergent BioSolutions

Industry

Biotechnology

Employees

900

CEO

Joseph C. Papa, MBA

Headquarters

Gaithersburg, MD 20879, US

EBS Financials

Key Financial Metrics (TTM)

Gross Margin

47%

Operating Margin

15%

Net Income Margin

7%

Return on Equity

10%

Return on Capital

9%

Return on Assets

4%

Earnings Yield

10.33%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$414.71M

Shares Outstanding

51.64M

Volume

190.79K

Short Interest

0.00%

Avg. Volume

831.69K

Financials (TTM)

Gross Profit

$350.60M

Operating Income

$110.20M

EBITDA

$208.50M

Operating Cash Flow

$170.60M

Capital Expenditure

$13.80M

Free Cash Flow

$156.80M

Cash & ST Invst.

$205.40M

Total Debt

$572.10M

Emergent BioSolutions Performance Analysis

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q4 2025YOY CHG

Revenue

$148.70M

-23.6%

Gross Profit

$31.10M

-77.2%

Gross Margin

20.91%

N/A

Market Cap

$414.71M

N/A

Market Cap/Employee

$460.78K

N/A

Employees

900

N/A

Net Income

$54.60M

-74.4%

EBITDA

$6.90M

-67.1%

Quarterly Fundamentals

Name
Q4 2025YOY CHG

Net Cash

$366.70M

+35.7%

Accounts Receivable

$84.20M

-45.5%

Inventory

$343.40M

+10.2%

Long Term Debt

$572.10M

-15.0%

Short Term Debt

$0.00

-100.0%

Return on Assets

3.99%

N/A

Return on Invested Capital

9.29%

N/A

Free Cash Flow

$73.80M

+190.4%

Operating Cash Flow

$77.70M

+197.2%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
ESPREsperion Therapeutics, Inc.
$1.98+3.40%
AQSTAquestive Therapeutics, Inc.
$4.12+0.86%
SNDLSNDL Inc.
$1.52+0.44%
SIGASIGA Technologies, Inc.
$4.62+0.98%

Trending Stocks

Symbol / CompanyPricePrice Chg
POETPoet Technologies
$7.51-0.50%
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares
$12.09-0.01%
SGMTSagimet Biosciences
$8.61+0.47%
TQQQProShares Trust - ProShares UltraPro Qqq
$62.33-0.00%

Questions About EBS

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.